Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Signum, GSK in R&D Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Signum, GSK in R&D Pact

Companies to screen and identify PP2A targeted compounds

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Signum Biosciences has entered into an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to collaborate on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

Signum will receive research support and milestone payments. GSK will have exclusive rights to Signum’s phosphatase screening technology for R&D activities in neurosciences. Both companies will screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.

Maxwell Stock, president of Signum, said, “GSK is an ideal partner for Signum. We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies. We are proud to be working in collaboration with a leading pharmaceutical company in innovative R&D. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics